United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $467.55, for a total value of $1,870,200.00. Following the sale, the chief executive officer owned 130 shares in the company, valued at $60,781.50. The trade was a 96.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

United Therapeutics Trading Up 1.0%

Shares of UTHR opened at $476.59 on Wednesday. The company has a market cap of $20.52 billion, a price-to-earnings ratio of 18.06, a PEG ratio of 4.96 and a beta of 0.77. The company’s fifty day simple moving average is $435.39 and its 200 day simple moving average is $352.54. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $485.32.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s revenue was up 6.8% on a year-over-year basis. During the same period last year, the business posted $6.39 EPS. As a group, research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of research reports. UBS Group raised their target price on shares of United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Wednesday. Royal Bank Of Canada raised their target price on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Cantor Fitzgerald upped their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Finally, Bank of America lifted their price target on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $503.90.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB grew its position in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the period. Chung Wu Investment Group LLC acquired a new position in United Therapeutics during the second quarter worth $29,000. Abich Financial Wealth Management LLC bought a new position in shares of United Therapeutics in the third quarter valued at $44,000. SVB Wealth LLC acquired a new position in shares of United Therapeutics during the first quarter valued at about $32,000. Finally, WealthCollab LLC increased its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.